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EDITORIAL
Polarizing  or paralyzing?  Moving  forward  with  patient  reported
outcome measurement  in irritable  bowel syndrome
¿Polarizar  o  paralizar?  Moviéndonos  hacia  variables  de  desenlace
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Patients  typically  seek  health  care  because  they  experi-
ence  symptoms.  Health  care  providers  must  elicit,  measure,
and  interpret  patient  symptoms  as  part  of  their  clini-
cal  evaluation.  Patient-generated  reports,  also  known  as
Patient-Reported  Outcomes  (PROs),  capture  the  patients’
illness  experience  in  a  structured  format  and  may  help
bridge  the  gap  between  patients  and  providers.  The  United
States  Food  and  Drug  Administration  (FDA)  deﬁnes  a  PRO  as
‘‘any  report  of  the  status  of  a  patient’s  health  condition
that  comes  directly  from  the  patient,  without  interpre-
tation  of  the  patient’s  response  by  a  clinician  or  anyone
else.’’1
PROs  measure  aspects  of  patient-reported  health  (e.g.
physical,  emotional,  or  social  symptoms)  and  can  help  to
direct  care  and  improve  clinical  results.  When  clinicians
systematically  collect  patient-reported  data  in  the  right
place  at  the  right  time,  PRO  measurement  can  effectively
aid  in  detection  and  management  of  conditions,2,3 improve
satisfaction  with  care,4 and  enhance  the  patient--provider
relationship.4--8
In  addition  to  their  use  in  clinical  practice,  PROs  also
play  an  important  role  in  clinical  trials  and  other  research
endeavors.  For  example,  health  related  quality  of  life
(HRQOL),  a  sub-type  of  PRO  that  measures  biopsychoso-
cial  health,  has  gained  traction  as  an  outcome  in  clinical
research,  including  clinical  trials.  HRQOL  measures  can
document  patient  improvement  or  decrement  over  time,
and  help  to  estimate  the  beneﬁts  of  clinical  interven-
tions.  In  addition,  the  FDA  now  considers  the  patient  report
in  drug  approval,  and  has  developed  guidance  for  use  of
PROs  in  clinical  trials.1 The  National  Institute  of  Health
(NIH)  has  also  supported  a  major  PRO  initiative,  called  the
Patient  Reported  Outcome  Measurement  Information  System
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PROMIS®;  www.nihpromis.org), designed  to  develop  and
valuate  several  PRO  domains.9,10 Our  group  is  developing
he  GI  symptom  measures  within  PROMIS.  Finally,  the  rising
rominence  of  the  Chronic  Care  Model,  which  emphasizes
he  centrality  of  the  provider--patient  relationship  in  clini-
al  decision  making,2,3 and  places  the  patient  report  in  the
orefront  of  activity  or  consideration  of  health  care.  In  short,
here  is  a  conﬂuence  of  scientiﬁc,  regulatory,  and  political
actors  that  amplify  the  importance  of  PRO  research.
Gastrointestinal  (GI)  illnesses  can  lead  to  physical,
ental,  and  social  distress.11 For  this  reason,  patients,
roviders,  investigators,  and  regulators  are  interested  in
sing  PROs  to  guide  clinical  decision-making,  conduct
linical  research,  and  achieve  drug  approval  in  GI.  The
onceptual  framework  in  Fig.  1  represents  our  current
nderstanding  of  GI  symptoms,  based  on  research  previously
erformed  by  our  group  in  patients  with  irritable  bowel  syn-
rome  (IBS).12 In  our  work  for  the  NIH  PROMIS  consortium  we
ound  that  this  model  applies  across  all  conditions  marked  by
I  symptoms  --  not  just  IBS.  The  current  GI  symptom  frame-
ork  posits  that  GI  symptoms  are  captured  by  8  domains:
1)  Belly  Pain;  (2)  Bloat/Gas;  (3)  Diarrhea;  (4)  Constipa-
ion;  (5)  Bowel  Incontinence/Soilage;  (6)  Heartburn/Reﬂux;
7)  Swallowing;  and  (8)  Nausea/Vomiting.
In  the  absence  of  ﬁnalized  PROMIS  measures  and  fully  val-
dated  symptom  indices  in  IBS,  the  FDA  employs  ‘‘interim
ndpoints’’  that  drug  manufacturers  can  use  while  groups
evelop  new  PROs  for  IBS  clinical  trials.  The  interim  end-
oints  apply  to  both  IBS  with  constipation  (IBS-C)  and  IBS
ith  diarrhea  (IBS-D),  and  measure  two  aspects  of  IBS:
1)  abdominal  pain  and  (2)  abnormal  defecation  (comprising
tool  frequency  and  stool  form).  Abdominal  pain  is  measured
ith  an  11-point  numeric  rating  scale  (NRS),  ranging  from  0
no  pain)  to  10  (worst  possible  pain).  We  previously  validated
he  NRS  in  IBS.13 Stool  form  is  measured  using  the  Bristol
tool  Scale  (BSS),  a  7-point  index  that  presents  stools  span-
ing  the  diarrhea  to  constipation  spectrum  (Fig.  2).  Finally,
. Published by Masson Doyma México S.A. All rights reserved.
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Domain Subdomain
Belly pain
Bloat/Gas
Bloating sensation
(e.g. feeling pressure or fullness)
Bloating appearance
(e.g. belly swollen or larger
than usual size)
Flatulence
(e.g. passing gas)
Diarrhea
Constipation
GI symptoms
Bowel incontinence/Soilage
(e.g. accidents)
Swallowing
Nausea/Vomiting
Heartburn/Reflux
Facets
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oFigure  1  Conceptual  model  of  GI  symptom
tool  frequency  is  measured  by  patient  self-report  using  a
aily  stool  diary.
According  to  the  FDA,  a  treatment  response  in  IBS
equires  simultaneous  improvement  in  abdominal  pain
nd  abnormal  defecation,  both  comprising  ‘‘co-primary’’
ndpoints.14 In  both  IBS-C  and  IBS-D,  a  pain  response  is
eﬁned  by  an  improvement  of  ≥30%  on  the  NRS  when
omparing  weekly  NRS  averages  over  time  vs.  baseline.
nterpretation  of  a  defecatory  response  varies  depending  on
Type 1 Separate hard lumps, like nuts(hard to pass)
Sausage-shaped but lumpy
Like a sausage but with cracks on
its surface
Like a sausage or snake, smooth
and soft
Soft blobs with clear-cut edges
(passed easily)
Fluffy pieces with ragged edges, a
mushy stool
Watery, no solid pieces,
Entirely liquid
Bristol stool chart
Type 2
Type 3
Type 4
Type 5
Type 6
Type 7
Figure  2  Bristol  Stool  Scale.
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iderlying  GI  PROMIS  item  bank  development.
he  IBS  sub-type.  For  IBS-D,  improvement  is  deﬁned  by  main-
aining  an  average  stool  form  of  ≤5  on  the  BSS  for  at  least
0%  of  the  time.  For  IBS-C,  the  FDA  requires  ≥1  complete
pontaneous  bowel  movement  (CSBM)  per  week,  regardless
f  BSS  results.
Let’s  face  it:  this  is  confusing,  if  not  cognitively  para-
yzing.  With  the  exception  of  investigators  working  closely
n  IBS  clinical  trials,  most  clinicians  are  unaware  of  these
eﬁnitions  or  ﬁnd  them  difﬁcult  to  memorize;  they  are  not
articularly  intuitive,  either.  But  they  serve  their  role  while
roups  create  better  endpoints.  We  expect  improved  PROs
o  arrive  in  the  next  1--2  years  as  groups  like  the  Criti-
al  Pathway  (C-Path)  Institute15 develop  multi-dimensional
ndpoints  for  IBS  clinical  trials.
In  this  issue  of  Revista  de  Gastroenterología  de  México,
ópez-Alvarenga  and  colleagues  present  a  novel  approach
o  PRO  measurement  in  IBS.  Called  the  ‘‘polar  vector’’
ethod,  the  approach  involves  measuring  stool  frequency
nd  form  using  a  BSS  ‘‘matrix,’’  and  then  converting  the
atrix  data  into  vectors  that  track  changes  in  stool  fre-
uency  and  form  over  time.  The  approach  borrows  from
asic  geometry,  which  allows  calculation  of  a  direction  and
agnitude  of  a  vector  between  two  points.  The  mathematics
f  this  approach  is  outlined  in  the  paper  and  accompanying
echnical  appendix;  I  do  not  review  the  geometry  further  in
his  editorial  (quite  honestly,  I  had  to  open  my  high  school
eometry  text  book  to  intuit  the  mathematics  of  this  paper).
To  test  their  concept,  the  authors  employed  data  from
 large,  open-label,  prospective  study  using  pinaverium
romide  and  simethicone  over  four  weeks  in  patients  with
BS  meeting  Rome  criteria.  The  study  measured  stool  con-
istency  and  frequency  along  with  improvements  in  cardinal
BS  symptom  intensity.  Using  data  from  1.677  patients
n  the  study,  the  authors  created  a  so-called  ‘‘omnibus
‘
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variable’’  that  accounted  for  stool  consistency  (BSS  type)
and  frequency,  and  employed  a  ‘‘two-dimensional  conﬁ-
guration  using  polar  vectors’’  to  display  the  results.  The
authors  explain  that  the  higher  the  value  of  the  BSS  type
and  the  frequency  of  the  bowel  movements,  the  greater
the  value  of  the  ‘‘polar  vector.’’
Using  this  approach,  the  authors  report  ‘‘polar  vector
analysis  made  it  possible  to  show  that  there  was  consid-
erable  improvement  in  the  IBS-C  patients  within  the  ﬁrst
two  weeks  of  treatment  and  that  it  remained  steady  dur-
ing  the  ﬁnal  two  weeks.’’  The  authors  do  not  deﬁne  what
‘‘considerable  improvement’’  means,  or  track  the  changes
in  polar  vector  magnitude  against  patient-reported  meas-
ures  of  improvement,  such  as  the  Guyatt  overall  treatment
effect  (OTE)  scale,  as  recommended  by  the  FDA.  Nonethe-
less,  they  visually  demonstrate  changes  in  the  ‘‘omnibus
variable’’  using  visually  dramatic  coordinate  scales  -- an
unusual,  if  not  spectacular,  results  graphic  for  an  IBS  clinical
trial.  The  investigators  further  report  that  a  vector  magni-
tude  of  12.5  ‘‘is  apparently  equal  to  a  type  4  on  the  Bristol
Stool  Scale.’’  I  am  unclear  precisely  how  that  apparent  equa-
tion  was  achieved,  but  am  pleased  to  see  an  attempt  to
lend  clinical  interpretation  to  these  mathematical  concepts.
Finally,  the  authors  show  how  the  behavior  of  the  polar  vec-
tor  varied  by  IBS  sub-groups  and  as  a  function  of  the  study
duration.
In  their  discussion  section,  the  authors  draw  wide  conclu-
sions  regarding  the  potential  beneﬁts  of  the  polar  vector
approach  in  IBS  PRO  measurement.  In  particular,  the  authors
describe  their  approach  is  a  ‘‘useful  method’’  for  evaluat-
ing  IBS  pharmacological  therapies,  and  point  out  that  the
approach  meets  many  of  the  FDA  PRO  requirements,  includ-
ing  a  focus  on  stool  consistency  and  frequency,  employing
daily  symptom  diaries,  and  employing  a  ‘‘multidimensional
context.’’
Although  the  approach  is  quite  novel  and  graphically
stimulating,  it  remains  unclear  to  what  degree  this  tech-
nique  meets  FDA  requirements  or  moves  us  forward  in
IBS  PRO  measurement.  First,  although  the  technique  may
indeed  be  ‘‘useful’’  to  distinguish  among  IBS  subgroups  in
an  uncontrolled,  open-label  study,  the  role  of  this  tech-
nique  in  Phase  III  registration  studies  remains  unclear  (as
the  authors  imply  in  their  limitations  section).  The  term
‘‘useful’’  is  generally  substituted  with  ‘‘valid’’  in  the  psy-
chometric  literature.  For  a  PRO  to  be  ‘‘valid’’  for  the  FDA,
it  must  demonstrate  face  validity  (i.e.  looks  ‘‘good’’  on
its  face),  content  validity  (i.e.  patients  support  its  content
through  focus  groups  and  cognitive  interviews),  construct
validity  (i.e.  its  scores  track  with  scores  of  already  vali-
dated  legacy  instruments),  and  criterion  validity  (i.e.  its
scores  vary  meaningfully  against  the  gold  standard  metric  --
in  this  case  something  like  a  patient  OTE).  The  polar  vector
approach  does  not  yet  achieve  these  levels  of  validity.
In  addition,  it  is  unclear  whether  the  approach  achieves
a  ‘‘multidimensional’’  status,  as  suggested  by  the  authors.
A  beneﬁt  of  the  approach  is  its  simultaneous  capture  of  both
stool  frequency  and  form  into  one  metric.  But  when  the  FDA
describes  a  multidimensional  PRO,  it  typically  refers  to  a
multi-domain  PRO  within  a  broader  conceptual  framework.
In  IBS,  a  multi-domain  PRO  should  indeed  not  only  measure
stool  frequency  and  form,  but  also  stool  urgency  (for  IBS-D),
straining  (for  IBS-C),  bloating  (including  how  bloating
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‘looks’’  vs.  ‘‘feels’’),  and  pain.  The  vector  approach
escribed  in  this  paper  falls  short  of  this  multi-domain
ision,  but  is  a  helpful  approach  for  getting  us  started.
The  success  of  the  polar  vector  approach  depends
ntirely  on  the  validity  of  its  underlying  components  -- in
his  case,  the  BSS  itself.  The  mathematical  manipulations
f  the  BSS  data  in  this  study  are  impressive  and  noteworthy,
ut  they  cannot  overcome  inherent  limitations  in  the
nderlying  data.  Although  the  BSS  correlates  with  intestinal
ransit  time  and  is  widely  endorsed  as  a  measure  of  stool
onsistency  in  IBS,  there  has  been  surprisingly  little  work
o  evaluate  IBS  patient  understanding  of  the  BSS.  We  previ-
usly  performed  qualitative  cognitive  de-brieﬁng  interviews
o  solicit  patient  views  about  the  BSS.16 For  example,  we
howed  the  BSS  to  patients  and  asked:  ‘‘Do  you  understand
hat  this  question  is  asking  you  to  do?
What  we  found  was  quite  illuminating.  In  a  study  with  43
ome  positive  IBS  patients,  we  found  that  most  expressed
reas  of  confusion  regarding  the  BSS.  83%  noted  that  a  sin-
le  bowel  movement  may  be  characterized  by  multiple  BSS
orms  (e.g.  ‘‘Sometimes  it  will  start  out  very  hard  and  then
ind  up  liquid’’),  and  noted  that  it  would  be  inaccurate  to
ssign  a  single  consistency  to  their  bowel  movement.  Many
atients  noted  that  they  have  multiple  bowel  movements
ithin  a  single  bathroom  visit,  and  that  different  bowel
ovements  often  have  different  forms.  These  patients  also
mphasized  that  it  can  be  difﬁcult  to  determine  the  ‘‘start’’
nd  ‘‘end’’  of  a  bowel  movement  (e.g.  ‘‘If  I get  up  from
he  toilet,  but  then  come  back  a  few  minutes  later,  does
hat  ‘count’  as  a  new  BM?  Do  I  assign  one  form  for  each
M,  or  different  forms  for  different  bathroom  visits?’’).  37%
oted  that  their  stool  consistency  varies  throughout  the  day.
hese  patients  could  not  identify  a  single  form  to  best  char-
cterize  the  day’s  bowel  movements  (e.g.  ‘‘Am  I  supposed
o  give  you  the  average  over  all  my  BMs  for  the  day?  A  typical
ay  involves  several  BMs  with  different  types;’’  ‘‘My  stool
n  the  morning  is  different  than  in  the  evening.’’).  Patients
mphasized  that  the  unit  of  measurement  was  unclear  (e.g.
ndividual  stool  vs.  bowel  movement  vs.  bathroom  visit),
nd  further  recommended  allowing  for  separate  forms  for
ach  bowel  movement,  and  to  assign  multiple  forms  within
athroom  visit.
In  short,  we  found  that  although  the  BSS  is  widely  used
nd  endorsed  by  the  FDA  and  Rome  criteria,  many  patients
oice  practical  concerns  about  how  to  respond  to  this  scale.
f  the  BSS  is  to  be  included  in  a  future  IBS  PRO,  be  it  with
‘polar  vectors’’  or  not,  its  instructions  for  use  will  need
o  be  clariﬁed  to  address  pervasive  confusion.  In  addition,
he  scale  itself  may  require  some  retroﬁtting  to  address  its
sychometric  shortcomings.
Where  does  this  leave  us?  The  polar  vector  approach  is
 novel  heuristic  for  visualizing  symptom  changes  in  IBS.
or  that  reason  alone,  it  is  a  useful  technique  for  modifying
ow  we  conceive  of  PRO  data,  not  only  in  IBS,  but  also
n  other  gastrointestinal  conditions.  On  the  other  hand,
he  polar  vector  technique  is  potentially  ‘‘paralyzing,’’
nsofar  as  it  is  difﬁcult  to  explain,  difﬁcult  to  calculate,  and
currently)  difﬁcult  to  interpret  clinically  using  legacy
enchmarks.  As  difﬁcult  as  the  current  FDA  interim  end-
oints  are  to  master,  the  polar  vector  technique  appears  to
dd  another  layer  of  complexity  atop  an  already  imperfect
nd  oftentimes  confusing  metric.
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In  order  to  make  new  headway  in  creating  PROs  for
egistration  trials,  we  should  break  away  from  paralyzing
omplexity,  and  focus  principally  on  PROs  built  from  patient-
erived  focus  groups  coupled  with  FDA  best  practices  for
rafting  multi-dimensional  instruments  grounded  in  a  priori
onceptual  frameworks,  as  supported  by  the  FDA  PRO  Guid-
nce  document.  In  the  meantime,  the  polar  vector  approach
ives  us  a  lot  to  think  about  and  seems  worth  further  inves-
igation  to  help  push  us  forward  in  IBS  PRO  measurement.
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